Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 and PR1 Peptide Vaccines for Low-Risk Myeloid Malignancies
NCT00488592Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jun 2007
- Primary completion
- Apr 2010
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of WT1 126-134 peptide, PR1 leukemia peptide vaccine in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), sponsored by National Heart, Lung, and Blood Institute. Started Jun 2007; status: completed.
02
Drugs
WT1 126-134 peptidePR1 leukemia peptide vaccine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00488592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00488592.